Florida is currently home to 3835 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Miami, Tampa, Jacksonville and Orlando. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Phase 2 Study of MZE829 in Adults with APOL1 Kidney Disease
Recruiting
This is purpose of this study is to evaluate the safety, tolerability, and effect on Albuminuria of MZE829 in Adults with APOL1 Kidney Disease
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/12/2025
Locations: Clinical Research of Brandon, LLC, Brandon, Florida
Conditions: Proteinuric Kidney Disease
Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects with Myasthenia Gravis
Recruiting
Phase 1b/2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-106.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
02/12/2025
Locations: Atlantis Research, Miami, Florida
Conditions: Myasthenia Gravis, Generalized Myasthenia, AChR Myasthenia Gravis, MuSK MG
ATA-200 Dose-escalation Gene Therapy Trial in Patients with LGMDR5
Recruiting
The purpose of ATA-003-GSAR study is to evaluate the safety and tolerability of a single intravenous infusion of ATA-200 in pediatric patients with limb girdle muscular dystrophy type 2c/R5 (LGMD R5). Patients will be treated sequentially in 2 dose-cohorts.
Gender:
ALL
Ages:
Between 6 years and 13 years
Trial Updated:
02/12/2025
Locations: Child Health Research Institute, Gainsville, Florida
Conditions: LGMD2C
Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy
Recruiting
This Phase 3, multicenter, double-masked, parallel-group, placebo-controlled, randomized, fixed-dose clinical study is designed to evaluate the efficacy and safety of tinlarebant (LBS-008) in subjects diagnosed with GA.
Gender:
ALL
Ages:
Between 60 years and 85 years
Trial Updated:
02/12/2025
Locations: Belite Study Site, Lakeland, Florida
Conditions: Geographic Atrophy
PK and Safety Study of Natroba Topical Suspension 0.9% in Subjects 1 Month to 3 Years 11 Months of Age with Scabies
Recruiting
A population of approximately 50 pediatric subjects will be enrolled to assess the PK of spinosad and benzyl alcohol for 3 hours following a single, full-body topical application (open label) on a single in-clinic visit (Day 1, or Day 2 if screening only on Day 1). There will be approximately 50 subjects ages 1 month to 3 years 11 months of age enrolled with the goal of completing approximately 16 subjects. With assistance from a caregiver, Natroba will be applied over the entire body from the n... Read More
Gender:
ALL
Ages:
Between 1 month and 4 years
Trial Updated:
02/12/2025
Locations: L&C Professional Medical Research Institute, Miami, Florida
Conditions: Scabies
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Recruiting
Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring anaplastic lymphoma kinase (ALK), receptor tyrosine kinase encoded by the gene ROS1 (ROS1), or neurotrophic receptor kinase genes encoding TRK kinase family (NTRK1-3) alterations to estimate the Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) and select the Pediatric Recommended Phase 2 Dose (RP2D). P... Read More
Gender:
ALL
Ages:
25 years and below
Trial Updated:
02/12/2025
Locations: Arnold Palmer Hospital For Children, Orlando, Florida
Conditions: Locally Advanced Solid Tumors, Metastatic Solid Tumors, Lymphoma, Primary CNS Tumors
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ALG-097558 in Subjects with Renal Impairment and in Healthy Subjects with Normal Renal Function
Recruiting
This is a Phase 1 non-randomized, open-label, multiple dose, parallel-group study of ALG-097558 in subjects with severe renal impairment and subjects without renal impairment, matched for age, body weight and, to the extent possible, for gender. The primary purpose of this study is to characterize the effect of renal impairment on the plasma pharmacokinetics of ALG-097558 following administration of multiple, twice daily (Q12H) oral (PO) doses.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
02/11/2025
Locations: University of Miami, Miami, Florida
Conditions: COVID 19
Usability Study of the FemPulse System
Recruiting
The objective of the study is to demonstrate that the FemPulse System can be used as indicated in the Instructions for Use (IFU), as applicable.
Gender:
FEMALE
Ages:
21 years and above
Trial Updated:
02/11/2025
Locations: Holy Cross Women's Hospital, Fort Lauderdale, Florida
Conditions: Overactive Bladder
Maestro 1.1 Post-Market Registry
Recruiting
The objective of the study is to observe the real-life usage of the Maestro Platform for surgical assistance in laparoscopic surgery.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
02/11/2025
Locations: Lee Health, Fort Myers, Florida
Conditions: Surgery
Healthy Eating and Active Lifestyle (HEAL): Breast Cancer Program Outcomes
Recruiting
The goal of this single-group prospective study is to examine the impact of the Healthy Eating and Active Lifestyle (HEAL) Breast Cancer program on participants' perceived stress, biometrics, basic labs, lifestyle behaviors, self-efficacy, mental health, and quality of life. Participants will participate in an 8-week program of 90-minute virtual sessions each week to decrease risk of cancer recurrence. Program participants can choose to participate in the research study which will include data... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2025
Locations: AdventHealth, Orlando, Florida
Conditions: Breast Cancer
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
Recruiting
This is a Phase 1/2A study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2025
Locations: Florida Cancer Specialists & Research Institute, LLC, Fort Myers, Florida
Conditions: Solid Tumor, Adult, Refractory Cancer, Cutaneous Melanoma, Non-small Cell Lung Cancer, Endometrial Carcinoma (EC), Squamous Head and Neck Carcinoma, PMMR/MSS Adenocarcinoma of the Colon or Rectum
Developing and Testing Health Warning Labels on the ENDS Device
Recruiting
In this project, after systematically developing electronic nicotine delivery systems (ENDS) pictorial health warning labels (HWLs), a proven clinical lab model will be used to examine and test their effect when these are placed on the ENDS device on a variety of subjective (e.g. satisfaction, harm perception, nicotine dependence, intention to quit) and objective outcomes (e.g. plasma nicotine, puff topography) in young adults.
Gender:
ALL
Ages:
Between 21 years and 35 years
Trial Updated:
02/11/2025
Locations: Florida International University, Miami, Florida
Conditions: Electronic Cigarette Use